First Endovascular Neural Interface Eyed By New Firm Synchron
Executive Summary
The company launched in Silicon Valley on April 21 with plans to develop a device that can be delivered to the brain with a catheter to record neuron signals that might be used to control an advanced prosthetic.
You may also be interested in...
Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?
Making the Office of Therapeutic Biologics and Biosimilars a stand-alone office in CDER may allow it to add more expertise, but is there an appetite for another reorganization?
UK LifeSci Funding Boost – Medtech Research And Regulation To Benefit
Rebranded Health Innovation Networks, Biobanks and clinical trials get share of £650m UK funding earmarked to support research, manufacturing, skills development and access to diagnosis and treatment.
Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage
Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. In this case study, Scrip takes a deep dive into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations.